Journal of Korean Medicine for Obesity Research (한방비만학회지)

The Society of Korean Medicine for obesity Research (한방비만학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of Safety of Mahuang in Studies for Treatment of Obesity

비만 치료 연구에서 마황의 안전성 분석

  • Cho, Minjin (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongguk University) ;
  • Kim, Sungha (Korean Medicine Science Research Division, Korea Institute of Oriental Medicine) ;
  • Kim, Hojun (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongguk University) ;
  • Song, Mi Young (The Reset Korean Medical Clinic)
  • 조민진 (동국대학교 한의과대학 한방재활의학교실) ;
  • 김성하 (한국한의학연구원 한의과학연구부) ;
  • 김호준 (동국대학교 한의과대학 한방재활의학교실) ;
  • 송미영 (더리셋한의원)
  • Received : 2021.10.30
  • Accepted : 2021.11.23
  • Published : 2021.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The purpose of this study is to analyze the adverse events and safety of Mahuang used as anti-obesity treatment in Korean medicine. Methods: PubMed, EMBASE, Cochrane, KoreaMed, Oriental Medicine Advanced Searching Integrated System (OASIS) and SCIENCE-ON were used as searching for randomized controlled trials investigating the safety of Mahuang for treating obesity from January, 2000 to July, 2021. Results: Total 6 studies were included for analyzing. In most studies, heart rate was higher in experimental group than in placebo group with statistically significant difference. Both systolic and diastolic blood pressure had no significant differences between both groups, but systolic blood pressure got lower in experimental group. Most adverse events reported in experimental group were dry mouth, constipation, diarrhea, palpitation and insomnia, but serious adverse events were not reported. Conclusions: This study provides the evidence about the safety of Mahuang for treating obesity. However, increase of heart rate and minor adverse events could be occurred. Further study is needed to confirm the safety of Mahuang.

Keywords

Acknowledgement

본 연구는 보건복지부의 재원으로 '한국보건산업진흥원의 보건의료기술연구개발사업(HF20C0208 및 HF20C0020)'의 지원을 받아 수행되었음.

References

  1. Nam GE, Kim YH, Han KD, Jung JH, Rhee EJ, Lee WY. Obesity fact sheet in Korea, 2020: prevalence of obesity by obesity class from 2009 to 2018. J Obes Metab Syndr. 2021 ; 30(2) : 141-2. https://doi.org/10.7570/jomes21056
  2. Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Current Obesity Reports. 2018 ; 7(2) : 147-61. https://doi.org/10.1007/s13679-018-0300-4
  3. KIOM. Obesity Korean medicine clinical practice guideline. Seoul : Elsevier Korea. 2016 : 84.
  4. The Co-textbook Publishing Committee of Korean Oriental Medicine School. Herbal medicine. Seoul : Younglimsa. 2016 : 153.
  5. Hwang MJ, Shin HD, Song MY. Review of literature on herbal medicines for the treatment of obesity in Korea: mainly papers since 2000. J Oriental Rehab Med. 2006 ; 16(3) : 65-81.
  6. Shannon JR, Gottesdiener K, Jordan J, Chen K, Flattery S, Larson PJ, et al. Acute effect of ephedrine on 24-h energy balance. Clinical Science. 1999 ; 96(5) : 483-91. https://doi.org/10.1042/CS19980206
  7. Jang IS, Yang CS, Hwang EH. The need for clinical practice guidelines in usage of Mahuang in weight loss. J Korean Med Obes Res. 2007 ; 7(1) : 23-9.
  8. Samenuk D, Link MS, Homoud MK, Contreras R, Theohardes TC, Wang PJ, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc. 2002 ; 77(1) : 12-6. https://doi.org/10.4065/77.1.12
  9. Jo GW, Ok JM, Kim SY, Lim YW. Review on the efficacy and safety of Mahuang and ephedrine in the treatment of obesity-focused on RCT. J Korean Med. 2017 ; 38(3) : 170-84. https://doi.org/10.13048/jkm.17034
  10. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011.
  11. Kim HJ, Park JM, Kim JA, Ko BP. Effect of herbal Ephedra sinica and Evodia rutaecarpa on body composition and resting metabolic rate: a randomized, double- blind clinical trial in Korean premenopausal women. J Acupunct Meridian Stud. 2008 ; 1(2) : 128-38. https://doi.org/10.1016/S2005-2901(09)60033-9
  12. Boozer CN, Daly PA, Homel P, Solomon JL, Blanchard D, Nasser JA, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. International Journal of Obesity. 2002 ; 26(5) : 593-604. https://doi.org/10.1038/sj.ijo.0802023
  13. Greenway F L, D e Jonge L, B lanchard D , F risard M , Smith SR. Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. Obesity Research. 2004 ; 12(7) : 1152-7. https://doi.org/10.1038/oby.2004.144
  14. Hackman RM, Havel PJ, Schwartz HJ, Rutledge JC, Watnik MR, Noceti EM, et al. Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial. International Journal of Obesity. 2006 ; 30(10) : 1545-56. https://doi.org/10.1038/sj.ijo.0803283
  15. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. International Journal of Obesity. 2001 ; 25(3) : 316-24. https://doi.org/10.1038/sj.ijo.0801539
  16. Coffey CS, Steiner D, Baker BA, Allison DB. A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. International Journal of Obesity. 2004 ; 28(11) : 1411-9. https://doi.org/10.1038/sj.ijo.0802784
  17. Kim HJ, Han CH, Lee EJ, Song YK, Shin BC, Kim YK. A clinical practice guideline for Ma-huang (Ephedra sinica) prescription in obesity. J Korean Med Obes Res. 2007 ; 7(2) : 27-37.
  18. Drew CD, Knight GT, Hughes DT, Bush M. Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. Br J Clin Pharmacol. 1978 ; 6(3) : 221-5. https://doi.org/10.1111/j.1365-2125.1978.tb04588.x
  19. Persky AM, Berry NS, Pollack GM, Brouwer KL. Modelling the cardiovascular effects of ephedrine. Br J Clin Pharmacol. 2004 ; 57(5) : 552-62. https://doi.org/10.1111/j.1365-2125.2003.02062.x
  20. Hsing LC, Lee TH, Son DH, Yeo JJ, Yang CS, Seo ES, et al. Adverse effects of Ma-huang according to dose: a randomized double-blind placebo-controlled pilot study. Korean J Orient Int Med. 2006 ; 27(1) : 188-96.
  21. Palamar J. How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. Health Policy. 2011 ; 99(1) : 1-9. https://doi.org/10.1016/j.healthpol.2010.07.007